Gladell P Paner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/401808/publications.pdf

Version: 2024-02-01

81 papers

3,402 citations

186265
28
h-index

56 g-index

82 all docs 82 docs citations

times ranked

82

3954 citing authors

#	Article	IF	CITATIONS
1	Should Grade Group 1 (GG1) be called cancer?. World Journal of Urology, 2022, 40, 15-19.	2.2	11
2	Multiâ€Site Concordance of Diffusionâ€Weighted Imaging Quantification for Assessing Prostate Cancer Aggressiveness. Journal of Magnetic Resonance Imaging, 2022, 55, 1745-1758.	3.4	11
3	Spectrum of biphasic renal cell carcinomas with hyalinized stroma and psammoma bodies associated and not associated with NF2 alteration. Human Pathology, 2022, 121, 11-18.	2.0	4
4	Updates in Grading of Renal Cell Carcinomas Beyond Clear Cell Renal Cell Carcinoma and Papillary Renal Cell Carcinoma. Advances in Anatomic Pathology, 2022, 29, 117-130.	4.3	5
5	Histological validation of prostate tissue composition measurement using hybrid multi-dimensional MRI: agreement with pathologists' measures. Abdominal Radiology, 2022, 47, 801-813.	2.1	6
6	Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. Journal of Clinical Oncology, 2022, 40, 3110-3114.	1.6	41
7	Flat intraurothelial lesions of the urinary bladder—do hyperplasia, dysplasia, and atypia of unknown significance need to exist as diagnostic entities? and how to handle in routine clinical practice. Modern Pathology, 2022, 35, 1296-1305.	5.5	4
8	Re: J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 2021;79:82–104. European Urology, 2021, 79, e30-e32.	1.9	5
9	College of American Pathologists Cancer Protocols: From Optimizing Cancer Patient Care to Facilitating Interoperable Reporting and Downstream Data Use. JCO Clinical Cancer Informatics, 2021, 5, 47-55.	2.1	18
10	Seminal vesicle cystadenoma with dysplasia: missing link to adenocarcinoma?. Histopathology, 2021, 79, 274-276.	2.9	3
11	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Advances in Anatomic Pathology, 2021, 28, 196-208.	4.3	20
12	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. Advances in Anatomic Pathology, 2021, 28, 179-195.	4.3	23
13	Similarities and Differences in the 2019 ISUP and GUPS Recommendations on Prostate Cancer Grading: A Guide for Practicing Pathologists. Advances in Anatomic Pathology, 2021, 28, 1-7.	4.3	18
14	Mesonephric (Wolffian-derived) Adenocarcinoma of the Female Urethra. American Journal of Surgical Pathology, 2021, 45, 543-549.	3.7	5
15	Mutational Profile Using Next-Generation Sequencing May Aid in the Diagnosis and Treatment of Urachal Adenocarcinoma. International Journal of Surgical Pathology, 2020, 28, 51-59.	0.8	6
16	Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies. Human Pathology, 2020, 106, 54-61.	2.0	5
17	The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2020, 44, e87-e99.	3.7	292
18	Potential biomarkers and risk assessment models to enhance the tumor-node-metastasis (TNM) staging classification of urologic cancers. Expert Review of Molecular Diagnostics, 2020, 20, 921-932.	3.1	2

#	Article	IF	CITATIONS
19	Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer. Cells, 2020, 9, 2116.	4.1	12
20	Radio-pathomic mapping model generated using annotations from five pathologists reliably distinguishes high-grade prostate cancer. Journal of Medical Imaging, 2020, 7, 054501.	1.5	15
21	Editorial Comment. Journal of Urology, 2020, 204, 265-266.	0.4	0
22	Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder. World Journal of Urology, 2019, 37, 107-114.	2.2	50
23	Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy. European Urology Focus, 2019, 5, 416-424.	3.1	20
24	Plasmacytoid Urothelial Carcinoma: An Unusual Variant That Warrants Aggressive Management and Critical Distinction on Transurethral Resections. Archives of Pathology and Laboratory Medicine, 2019, 143, 1562-1567.	2.5	20
25	â™,♀Cystic and Solid Tumors of the Urachus vs. Gynecologic Tract Tumors: Similarities and Differences. , 2019, , 316-330.		0
26	Patterns of Urachal Remnant Involvement by Urothelial Carcinoma. American Journal of Surgical Pathology, 2019, 43, 475-479.	3.7	3
27	Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer. European Urology Focus, 2019, 5, 433-442.	3.1	27
28	Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. European Urology, 2018, 73, 560-569.	1.9	401
29	Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase–deficient Renal Cell Carcinoma. American Journal of Surgical Pathology, 2018, 42, 279-292.	3.7	101
30	The New Realization About Cribriform Prostate Cancer. Advances in Anatomic Pathology, 2018, 25, 31-37.	4.3	58
31	Contemporary Grading and Staging of Urothelial Neoplasms of the Urinary Bladder. Surgical Pathology Clinics, 2018, 11, 775-795.	1.7	9
32	Reply to Vincenzo Di Nunno, Matteo Santoni, Alessia Cimadamore, Nicola Battelli, and Francesco Massari's Letter to the Editor re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, et al. Updates in the Eight Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. Eur Urol 2018;73:560–9. European Urology, 2018, 74, e120-e121.	1.9	0
33	Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 85-93.	2.8	26
34	Circulating tumor cells capture disease evolution in advanced prostate cancer. Journal of Translational Medicine, 2017, 15, 44.	4.4	27
35	Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances. Advances in Anatomic Pathology, 2017, 24, 113-127.	4.3	47
36	Lymphoepithelioma-like carcinoma of the upper urinary tract. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 703-709.	2.8	22

#	Article	lF	Citations
37	latrogenic changes in the urinary tract. Histopathology, 2017, 70, 10-25.	2.9	25
38	Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer. European Urology, 2017, 72, 455-460.	1.9	28
39	Risk of lymph node metastases in pathological gleason scoreâ‰ ® prostate adenocarcinoma: Analysis of institutional and population-based databases. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 31.e1-31.e6.	1.6	14
40	In reply to: letter to the editor entitled: primary pure lymphoepithelioma-like carcinoma of the ureter. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 561-562.	2.8	0
41	Updates in the Pathologic Diagnosis and Classification of Epithelial Neoplasms of Urachal Origin. Advances in Anatomic Pathology, 2016, 23, 71-83.	4.3	67
42	Spectrum of Cystic Epithelial Tumors of the Prostate. American Journal of Surgical Pathology, 2016, 40, 886-895.	3.7	23
43	Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunology Research, 2016, 4, 563-568.	3.4	293
44	Clinically localized type $1\mathrm{and}2$ papillary renal cell carcinomas have similar survival outcomes following surgery. World Journal of Urology, 2016, 34, 687-693.	2.2	24
45	Urinary bladder xanthoma: a multiâ€institutional series of 17 cases. Histopathology, 2015, 67, 255-261.	2.9	7
46	Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer – A Case Report. Frontiers in Oncology, 2015, 5, 169.	2.8	10
47	Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. Urology, 2015, 86, 777-782.	1.0	26
48	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Modern Pathology, 2015, 28, 612-630.	5 . 5	106
49	Next-gen tissue: preservation of molecular and morphological fidelity in prostate tissue. American Journal of Translational Research (discontinued), 2015, 7, 1227-35.	0.0	7
50	Influence of Histologic Criteria and Confounding Factors in Staging Equivocal Cases for Microscopic Perivesical Tissue Invasion (pT3a). American Journal of Surgical Pathology, 2014, 38, 167-175.	3.7	16
51	Pseudoangiosarcomatous Urothelial Carcinoma of the Urinary Bladder. American Journal of Surgical Pathology, 2014, 38, 1251-1259.	3.7	17
52	Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence. Annals of Diagnostic Pathology, 2014, 18, 49-52.	1.3	30
53	Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. Human Pathology, 2014, 45, 1473-1482.	2.0	110
54	ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. European Urology, 2013, 63, 16-35.	1.9	107

#	Article	IF	CITATIONS
55	Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases. Human Pathology, 2013, 44, 860-866.	2.0	34
56	The different morphologies of urachal adenocarcinoma do not discriminate genomically by micro-RNA expression profiling. Human Pathology, 2013, 44, 1605-1611.	2.0	6
57	Validation of New AJCC Exclusion Criteria for Subepithelial Prostatic Stromal Invasion from pT4a Bladder Urothelial Carcinoma. Journal of Urology, 2013, 189, 53-58.	0.4	27
58	Urachal Carcinomas of the Nonglandular type. American Journal of Surgical Pathology, 2012, 36, 432-442.	3.7	51
59	Nonâ€epithelial neoplasms of the prostate. Histopathology, 2012, 60, 166-186.	2.9	29
60	Limited smoothelin expression within the muscularis mucosae: validation in bladder diverticula. Human Pathology, 2011, 42, 1770-1776.	2.0	26
61	Immunohistochemical Analysis in a Morphologic Spectrum of Urachal Epithelial Neoplasms. American Journal of Surgical Pathology, 2011, 35, 787-798.	3.7	66
62	Urothelial Neoplasms of the Urinary Bladder Occurring in Young Adult and Pediatric Patients. Advances in Anatomic Pathology, 2011, 18, 79-89.	4.3	73
63	Rete Testis-Associated Nodular Steroid Cell Nests. American Journal of Surgical Pathology, 2011, 35, 505-511.	3.7	16
64	A Novel Tumor Grading Scheme for Chromophobe Renal Cell Carcinoma. American Journal of Surgical Pathology, 2010, 34, 1233-1240.	3.7	125
65	Diagnostic Use of Antibody to Smoothelin in the Recognition of Muscularis Propria in Transurethral Resection of Urinary Bladder Tumor (TURBT) Specimens. American Journal of Surgical Pathology, 2010, 34, 792-799.	3.7	45
66	Primary Thyroid-like Follicular Carcinoma of the Kidney. American Journal of Surgical Pathology, 2009, 33, 393-400.	3.7	146
67	Diagnostic Utility of Antibody to Smoothelin in the Distinction of Muscularis Propria From Muscularis Mucosae of the Urinary Bladder. American Journal of Surgical Pathology, 2009, 33, 91-98.	3.7	77
68	Rhabdomyosarcoma of the Urinary Bladder in Adults: Predilection for Alveolar Morphology With Anaplasia and Significant Morphologic Overlap With Small Cell Carcinoma. American Journal of Surgical Pathology, 2008, 32, 1022-1028.	3.7	40
69	Best Practice in Diagnostic Immunohistochemistry: Prostate Carcinoma and Its Mimics in Needle Core Biopsies. Archives of Pathology and Laboratory Medicine, 2008, 132, 1388-1396.	2.5	70
70	Renal Cell Carcinoma and the Renal Sinus. Advances in Anatomic Pathology, 2007, 14, 63-68.	4.3	21
71	Further Characterization of the Muscle Layers and Lamina Propria of the Urinary Bladder by Systematic Histologic Mapping. American Journal of Surgical Pathology, 2007, 31, 1420-1429.	3.7	82
72	High Incidence of Chromosome 1 Abnormalities in a Series of 27 Renal Oncocytomas: Cytogenetic and Fluorescence In Situ Hybridization Studies. Archives of Pathology and Laboratory Medicine, 2007, 131, 81-85.	2.5	32

#	Article	IF	CITATIONS
73	Passive Seeding in Metanephric Adenoma: A Review of Pseudometastatic Lesions in Perinephric Lymph Nodes. Archives of Pathology and Laboratory Medicine, 2005, 129, 1317-1321.	2.5	23
74	A Retroperitoneal Mass in an Elderly Woman. Archives of Pathology and Laboratory Medicine, 2005, 129, 703-705.	2.5	2
75	Simultaneous Diffuse Sclerosis Variant of Papillary Thyroid Carcinoma and Diffuse Toxic Hyperplasia (Graves' Disease). Endocrine Pathology, 2004, 15, 77-82.	9.0	1
76	Analysis of the Effect of the Novel Histone Deacetylase Inhibitor, Depsipeptide (FK228/FR901228) on Mantle Cell Lymphoma Blood, 2004, 104, 2499-2499.	1.4	1
77	HIV and HHV-8 Negative Primary Effusion Lymphoma in a Patient with Hepatitis C Virus-related Liver Cirrhosis. Leukemia and Lymphoma, 2003, 44, 1811-1814.	1.3	59
78	Pathologic Quiz Case: A Cystic Mass in the Cerebellopontine Angle. Archives of Pathology and Laboratory Medicine, 2003, 127, e45-e46.	2.5	1
79	Parafallopian Tube Transitional Cell Carcinoma. Gynecologic Oncology, 2002, 86, 379-383.	1.4	19
80	Pathologic Quiz Case: Incidental Hepatic Nodule on Abdominal Laparotomy. Archives of Pathology and Laboratory Medicine, 2002, 126, 225-226.	2.5	0
81	Hepatoid carcinoma of the pancreas. Cancer, 2000, 88, 1582-1589.	4.1	94